
The Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM) study's phase 1b/2a trial assessed safety and efficacy of anti-CD362–selected, allogeneic mesenchymal stromal cells (ORBCEL-M) in adults with type 2 diabetes and progressive diabetic kidney disease. In the lowest dose cohort, ORBCEL-M therapy was safe and well-tolerated, with a significantly lower rate of estimated glomerular filtration rate decline compared to placebo over 18 months. The study suggests the potential of ORBCEL-M therapy in mitigating diabetic kidney disease progression.
Like
Save
Share